Abstract Details

Title Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-053

Objective To assess the relationship between brain volume changes in specific brain regions and disability progression in primary progressive multiple sclerosis (PPMS) patients.

Background

Although several studies have been performed about brain volume changes in patients with relapsing multiple sclerosis (RMS), there is scarce information of the effect of the neurodegenerative process in regional or global atrophy in disability and cognition in patients with PPMS.

Design/Methods

A prospective, observational study was conducted in adult patients with PPMS (McDonald 2010) from 11 MS Units in Spain. MR Imaging scans were processed using the tissue segmentation (white and grey matter) and the identification of 252 anatomic brain areas. Outlier samples were removed from statistical analysis. Regression and correlation analyses were performed to determine the relationship of anatomic areas and evidence of progression (EP) according to expanded disability status scale (EDSS) score or/and 9 hole-peg test (9HPT) or/and

Results Forty-four out of 55 patients were studied (mean age 55.8 (SD 9.5) years, 56.4% male). MS evolution mean time was 4.1 (SD 4.5) years and median EDSS score 5.5. Twenty (45%) patients had EP after 1-year of follow-up (1YFU). Baseline white matter (WM) adjacent to left amygdala (WMLA) and WM adjacent to right cerebellar tonsil (WMRCT) volumes showed differences between patients with EP and those with no EP (NEP) after 1YFU [(WMLA EP/NEP 0.56cm³/0.91cm³; P=0.01); (WMRCT EP/NEP 2.6cm³/3.1cm³, P=0.003)], as well as other 7 WM regions (P<0.05). Patients with a baseline cutoff point below 0.62cm³(WMLA) and 2.9cm³(WMRCT) were associated to a higher risk of EP after 1 year.

Conclusions

WMLA and WMRCT baseline volumes could be predictive of disease progression in PPMS patients after 1 year, as well as other WM specific regions.

Authors/Disclosures
Francisco Perez Miralles, MD PRESENTER	Dr. Perez Miralles has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mylan. Dr. Perez Miralles has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. Dr. Perez Miralles has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sanofi-Aventis. Dr. Perez Miralles has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
Daniel Prefasi	No disclosure on file
	No disclosure on file
Jose Ramon Ara, MD (Hospital Miguel Servet)	No disclosure on file
Guillermo Izquierdo Ayuso, MD (Servicio De Neurologia)	Dr. Izquierdo Ayuso has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer, Biogen Idec, Novartis, Sanofi, Merck Serono, Roche, Actelion and Celgene. Dr. Izquierdo Ayuso has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme, Novartis, Sanofi Aventis, Alexion.
Virginia Meca Lallana	Virginia Meca Lallana has nothing to disclose.
Francisco Gascon (Hospital Clinico de Valencia)	Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SANOFI. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MERCK. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ROCHE. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SANOFI. The institution of Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for NOVARTIS. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Francisco Gascon has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ALMIRALL.
Maria Luisa Martinez Gines, MD	Dr. Martinez Gines has nothing to disclose.
Lluis Ramio Torrenta	Lluis Ramio Torrenta has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI. Lluis Ramio Torrenta has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Lluis Ramio Torrenta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SANOFI. Lluis Ramio Torrenta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ROCHE. Lluis Ramio Torrenta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIOGEN. Lluis Ramio Torrenta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MERCK. Lluis Ramio Torrenta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Lluis Ramio Torrenta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ALMIRALL.
Lucienne Costa Frossard Franc	No disclosure on file
Oscar Fernandez, MD (Hospital Carlos Haya)	No disclosure on file
Sara Moreno Garcia, MD (Neurologia - Hospital Sevilla)	No disclosure on file
Jorge Maurino	Jorge Maurino has received personal compensation for serving as an employee of Roche Pharma Spain, Medical Department.
	No disclosure on file

��ɫ��

��ɫ��